# A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation

> **NCT04534855** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Treprilimab

## Key facts

- **NCT ID:** NCT04534855
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04534855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04534855, "A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04534855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*